Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 1
Submit an article Journal homepage
714
Views
22
CrossRef citations to date
0
Altmetric
Letters to the Editor

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

John D. HainsworthSarah Cannon Research Institute, Nashville, TN, USA;Tennessee Oncology, PLLC, Nashville, TN, USACorrespondence[email protected]
,
Edward R. ArrowsmithSarah Cannon Research Institute, Nashville, TN, USA;Tennessee Oncology, PLLC, Nashville, TN, USA
,
Michael McCleodSarah Cannon Research Institute, Nashville, TN, USA;Florida Cancer Specialists, Fort Myers, FL, USA
,
Eric D. HsiCleveland Clinic, Cleveland, OH, USA
,
Oday HamidEli Lilly and Company, Indianapolis, IN, USA
,
Peipei ShiEli Lilly and Company, Indianapolis, IN, USA
,
Boris K. LinEli Lilly and Company, Indianapolis, IN, USA
&
Luis E. FayadMD Anderson Cancer Center, Houston, TX, USA
 show all
Pages 216-218 | Received 10 Feb 2015, Accepted 20 Apr 2015, Published online: 08 May 2015

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Oren Pasvolsky, Alon Rozental, Pia Raanani, Anat Gafter-Gvili & Ronit Gurion. (2021) R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. Acta Oncologica 60:6, pages 744-749.
Read now
Hua-Jay J. Cherng & Jason Westin. (2021) Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. Leukemia & Lymphoma 62:6, pages 1302-1312.
Read now
Annalisa Chiappella, Elisa Santambrogio, Alessia Castellino, Maura Nicolosi & Umberto Vitolo. (2017) Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. Expert Review of Hematology 10:8, pages 697-705.
Read now

Articles from other publishers (19)

Gaelen Shimkus & Taichiro Nonaka. (2023) Molecular classification and therapeutics in diffuse large B-cell lymphoma. Frontiers in Molecular Biosciences 10.
Crossref
Gaelen Shimkus & Taichiro Nonaka. (2023) Molekulare Klassifizierung und Therapien des diffusen großzelligen B-Zell-Lymphoms. Kompass Onkologie 10:2, pages 59-76.
Crossref
Maike Stegemann, Sophy Denker & Clemens A. Schmitt. (2022) DLBCL 1L—What to Expect beyond R-CHOP?. Cancers 14:6, pages 1453.
Crossref
Aleksander Sergeevich Luchinin. (2022) Treatment of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Literature Review and Meta-Analysis. Clinical oncohematology 15:2, pages 130-139.
Crossref
Michael Y. He & Robert Kridel. (2021) Treatment resistance in diffuse large B-cell lymphoma. Leukemia 35:8, pages 2151-2165.
Crossref
Arushi Khurana, Raphael Mwangi, Grzegorz S. Nowakowski, Thomas M. Habermann, Stephen M. Ansell, Betsy R. LaPlant, Brian K. Link, James R. Cerhan, Matthew J. Maurer & Thomas E. Witzig. (2021) Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology 39:15, pages 1641-1649.
Crossref
Vicki A. Morrison. (2021) Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective. Journal of Geriatric Oncology 12:2, pages 320-325.
Crossref
Liang Wang, Lin-rong Li & Ken H. Young. (2020) New agents and regimens for diffuse large B cell lymphoma. Journal of Hematology & Oncology 13:1.
Crossref
Jennifer K Lue & Owen A O'Connor. (2020) A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. The Lancet Haematology 7:11, pages e838-e850.
Crossref
Stephen D. Smith, Brian G. Till, Mazyar S. Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian V. Wu, Jenna Voutsinas, Heather A. Rasmussen, Katherine Blue, Chaitra S. Ujjani, Andrei Shustov, Ryan D. Cassaday, Jonathan R. Fromm & Ajay K. Gopal. (2020) Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy. British Journal of Haematology 189:6, pages 1119-1126.
Crossref
Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, Joshua Brody, Xiuhua Sun, Joseph Maly, Yuqin Song, Syed Rizvi, Yongping Song, Frederick Lansigan, Hongmei Jing, Junning Cao, Jennifer K Lue, Wen Luo, Lei Zhang, Ling Li, Isabel Han, Joan Sun, Manoj Jivani, Young Liu, Thomas Heineman & Stephen D Smith. (2020) ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. Future Oncology 16:15, pages 991-999.
Crossref
Feifei Sun, Xiaosheng Fang & Xin Wang. (2020) Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma. Anti-Cancer Agents in Medicinal Chemistry 19:17, pages 2047-2059.
Crossref
Vicki A. Morrison, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent & Aaron Galaznik. (2020) Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015. Journal of Geriatric Oncology 11:1, pages 41-54.
Crossref
Yi Miao, L. Jeffrey Medeiros, Yong Li, Jianyong Li & Ken H. Young. (2019) Genetic alterations and their clinical implications in DLBCL. Nature Reviews Clinical Oncology 16:10, pages 634-652.
Crossref
Yi Miao, L. Jeffrey Medeiros, Zijun Y. Xu-Monette, Jianyong Li & Ken H. Young. (2019) Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Frontiers in Oncology 9.
Crossref
Brian G. Till. (2018) Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Current Treatment Options in Oncology 19:9.
Crossref
G. Iacoboni, E. Zucca, M. Ghielmini & A. Stathis. (2018) Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Annals of Oncology 29:5, pages 1120-1129.
Crossref
Vincent Prêtre & Andreas Wicki. (2018) Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?. Seminars in Cancer Biology 48, pages 70-77.
Crossref
N M Reddy, J P Greer, D S Morgan, H Chen, S I Park & K L Richards. (2016) A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. Leukemia 31:1, pages 241-244.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.